TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25677397
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with fluoxetine 20-40 mg/day plus IPT-BPD
Study: 21679182
Drug: High PCO2
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High PCO2 solution
Study: 21679182
Drug: 0.1 N
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 N HCl solution (acid perfusion)
Study: 19358119
Drug: Postoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative oral and nasal steroid therapy
Study: 17953808
Drug: Vitamin B12,
Normalized name: Vitamin B12, 50 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12, folic acid, L-carnitine, and betaine supplementation
Study: 2678805
Drug: 0‐(beta‐Hydroxylethyl)‐rutoside (HR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 600 mg
Study: 2678805
Drug: 0‐(beta‐Hydroxylethyl)‐rutoside (HR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 900 mg
Study: 2678805
Drug: 0‐(beta‐Hydroxylethyl)‐rutoside (HR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 1200 mg
Study: 2678805
Drug: 0‐(beta‐Hydroxylethyl)‐rutoside (HR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 1500 mg
Study: 1170119
Drug: Insulin 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 0.05 μ/kg body weight injected intravenously at 8 a.m.
Study: 1170119
Drug: Insulin 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 0.05 μ/kg body weight injected intravenously at 5 p.m.
Study: 1170119
Drug: Insulin injection
Normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin injection in the afternoon vs morning
Study: 1170119
Drug: Caloric change
Normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caloric change in plasma after insulin injection
Study: 1170119
Drug: Plasma growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma growth hormone response
Study: 28331291
Drug: DA-8031 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-8031 at doses of 5, 10, 20, 40, 60, 80, or 120 mg
Study: 28331291
Drug: DA-8031 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-8031 (80 mg or less)
Study: 26385201
Drug: Cannabis (12.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis (12.5% tetrahydrocannabinol), median daily dose of 2.5 g/d
Study: 22046230
Drug: Informed consent
Normalized name: Consensi
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Informed consent comprehension quiz administered at enrollment and during follow-up
Study: 11053903
Drug: Trovafloxacin 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 300 mg/24 h
Study: 11053903
Drug: Ciprofloxacin 400
Normalized name: ciprofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400 mg/12 h
Study: 11053903
Drug: Trovafloxacin 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 300 mg/24 h plus cefepime 2 g/12 h
Study: 11053903
Drug: Ciprofloxacin 400
Normalized name: ciprofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400 mg/12 h plus cefepime 2 g/12 h
Study: 11053903
Drug: Combination regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimens (both)
Study: 25907157
Drug: Maintenance antidepressants
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance antidepressants
Study: 26068110
Drug: Exogenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exogenous insulin delivery
Study: 10852359
Drug: Expressed desire
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expressed desire for treatment
Study: 10852359
Drug: Two or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two or more previous treatment admissions
Study: 10852359
Drug: Frequency of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency of injection
Study: 10852359
Drug: Giving money
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giving money or drugs for sex
Study: 10852359
Drug: Level of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level of injection-related risk for HIV infection
Study: 6383269
Drug: LYCD ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYCD ointment
Study: 6383269
Drug: Ointment base
Normalized name: Ointment base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment base (Control)
Study: 2880362
Drug: Perphenazine (20.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (20.5 mg/day)
Study: 2880362
Drug: Haloperidol (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5.5 mg/day)
Study: 2880362
Drug: Haloperidol (11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (11 mg/day) + Biperiden (7 mg/day)
Study: 2880362
Drug: Chlorprothixene (142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorprothixene (142 mg/day)
Study: 18410803
Drug: Day cream
Normalized name: Gyne-Lotrimin 3 Day Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day cream with photostable combination of UVB and UVA filters
Study: 10894871
Drug: Cyclophosphamide, methotrexate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, methotrexate, and fluorouracil (CMF) - 6 cycles; Cyclophosphamide 100 mg/m² orally days 1 to 14, Methotrexate 40 mg/m² IV days 1 and 8, Fluorouracil 600 mg/m² IV days 1 and 8
Study: 10894871
Drug: Tamoxifen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen plus ovarian suppression (5 years of tamoxifen 30 mg/d, plus surgical oophorectomy, ovarian irradiation, or monthly goserelin 3.6 mg injections)
Study: 8507018
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg nalbuphine
Study: 7760093
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg propofol
Study: 29655626
Drug: 3+1 (PCV7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3+1 (PCV7 booster after 3 priming doses)
Study: 29655626
Drug: 3+0 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3+0 (3 doses of PCV7)
Study: 29655626
Drug: 0+2 (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0+2 (control group, 12 and 18 months doses)
Study: 25518508
Drug: Cytoflavin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (2 tablets b.i.d. on days 1 to 25) during standard basic therapy
Study: 25518508
Drug: Standard basic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard basic therapy only
Study: 20136785
Drug: Alemtuzumab (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab (single dose)
Study: 15805318
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment followed by 5 minutes of 4% liposomal lidocaine cream
Study: 11420886
Drug: ARTEM (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARTEM (300 mg)
Study: 11420886
Drug: MQ (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: MQ (750 mg)
Study: 11420886
Drug: QN (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: QN (600 mg)
Study: 11420886
Drug: PQ (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: PQ (45 mg)
Study: 11420886
Drug: ARTEM (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARTEM (300 mg) + MQ (750 mg)
Study: 11420886
Drug: ARTEM (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARTEM (300 mg) + QN (600 mg)
Study: 11420886
Drug: ARTEM (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARTEM (300 mg) + PQ (45 mg)
Study: 25672892
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D (1,000 mg calcium carbonate and 400 IU vitamin D3 per day)
Study: 18231120
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of vitamin D drops containing 10 microg (400 IU) of ergocalciferol (vitamin D(2)) with information brochure
Study: 18231120
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of vitamin D drops
Study: 9399276
Drug: Infusion rate
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate (rapid infusion)
Study: 9399276
Drug: Infusion rate
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate (two rates studied in vivo)
Study: 9399276
Drug: Rapid infusion
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid infusion rate
Study: 3115780
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg day‐1 of flecainide
Study: 3115780
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg day‐1 of flecainide
Study: 28623471
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV lidocaine (1.5 mg kg−1 bolus then 1 mg kg−1 per hour)
Study: 28232170
Drug: Ketamine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (target plasma level=100ng/ml)
Study: 21328373
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (ETV or ADV)
Study: 19548415
Drug: Optosil/Xantopren L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optosil/Xantopren L (Heraeus Kulzer)
Study: 15169686
Drug: Olanzapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (mean modal dose= 9.63 mg/day)
Study: 15169686
Drug: Haloperidol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (mean modal dose=4.60 mg/day)
Study: 9845936
Drug: Naltrexone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone administered prophylactically for 6 months or longer
Study: 8919632
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg by single daily administration (Group A)
Study: 8919632
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg for the first 3 days, then 5 mg thereafter (Group B)
Study: 2184654
Drug: Indapamide in
Normalized name: Product containing indapamide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide in combination with captopril (group II)
Study: 2184654
Drug: Indapamide in
Normalized name: Product containing indapamide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide in combination with propranolol (group III)
Study: 6110803
Drug: Camazepam 40
Normalized name: halazepam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camazepam 40 mg
Study: 16921035
Drug: VACA-IE (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VACA-IE (chemotherapy with doxorubicin, vincristine, cyclophosphamide, dactinomycin alternating with ifosfamide and etoposide)
Study: 16921035
Drug: VACA (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VACA (chemotherapy with doxorubicin, vincristine, cyclophosphamide, dactinomycin)
Study: 2840172
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 10 mg/kg body weight/day for 20 days
Study: 2840172
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 10 mg/kg body weight/day for 40 days
Study: 2840172
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 15 mg/kg body weight/day for 20 days
Study: 2840172
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 15 mg/kg body weight/day for 40 days
Study: 2840172
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 20 mg/kg body weight/day for 20 days
Study: 2840172
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 20 mg/kg body weight/day for 40 days
Study: 2840172
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 20 mg/kg for 40 days
Study: 2840172
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 20 mg/kg for 20 days
Study: 2840172
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 15 mg/kg for 40 days
Study: 2840172
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 15 mg/kg for 20 days
Study: 2840172
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 10 mg/kg for 40 days
Study: 2840172
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 10 mg/kg for 20 days
Study: 28595147
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (random assignment to different antipsychotic treatment)
Study: 21501692
Drug: CIC‐HFA 282
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIC‐HFA 282 μg
Study: 21501692
Drug: CIC‐HFA 282
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIC‐HFA 282 μg and 148 μg
Study: 18440674
Drug: Plasmid pTHr
Normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmid pTHr DNA vaccine
Study: 18440674
Drug: Modified vaccinia
Normalized name: Modified vaccinia ankara
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified vaccinia virus Ankara (MVA) vaccine
Study: 16550943
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone for 2 weeks
Study: 16550943
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide after oral prednisone
Study: 16550943
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone and intranasal budesonide
Study: 7519702
Drug: Buspirone 15
Normalized name: busPIRone 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 15 mg
Study: 18362295
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy for 1 year
Study: 16818280
Drug: Bortezomib 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.0 or 1.3 mg/m2 administered intravenously twice weekly for 2 weeks of a 3-week cycle for up to 8 cycles plus oral dexamethasone 20 mg on the day of and after each bortezomib dose
Study: 14585874
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g human albumin
Study: 1425271
Drug: Glucose only
Normalized name: Glucose only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose only (2 mg/kg.min)
Study: 1425271
Drug: Glucose+xylitol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose+xylitol (1 mg/kg.min each)
Study: 1425271
Drug: Glucose-containing electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-containing electrolyte solution (0.83 mg/kg.min glucose)
Study: 6420383
Drug: Indomethacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (500 mg/3 days)
Study: 29517675
Drug: Shenmai (SM)
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai (SM) injection
Study: 29517675
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose (G)
Study: 24759827
Drug: Early ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early ART (initiated 2 weeks after tuberculosis treatment onset)
Study: 24759827
Drug: Late ART
Normalized name: Flavor PCCA Chocolate Artificial (Aldehyde Base)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late ART (initiated 8 weeks after tuberculosis treatment onset)
Study: 21300002
Drug: Subarachnoid hemorrhage
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subarachnoid hemorrhage treatment (coiling, clipping)
Study: 7790471
Drug: FAN bottles
Normalized name: danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAN bottles (subset of patients on antimicrobial therapy)
Study: 21327725
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg (R group)
Study: 21327725
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg plus fenofibrate 200 mg (RF group)
Study: 21327725
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg plus n-3 fatty acids 2 g (RN group)
Study: 16614537
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 1,200 mg/d
Study: 16614537
Drug: Mianserin 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 15 mg/d
Study: 15610312
Drug: Intralesional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional steroid injection (8 mg triamcinolone acetate into each quadrant)
Study: 9164424
Drug: Fluvoxamine (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50-150 mg/day, mean 102 +/- 44 mg/day)
Study: 9164424
Drug: Paroxetine (20-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20-50 mg/day, mean 36 +/- 13 mg/day)
Study: 2884494
Drug: Solid-phase radioimmunoassay
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid-phase radioimmunoassay for antibodies against neutrophil cytoplasm
Study: 27799299
Drug: Biobran (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biobran (1 g/day), n = 16
Study: 22099384
Drug: Polydextrose (PDX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydextrose (PDX; 8 g/d)
Study: 19035875
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg allopurinol for 8 weeks
Study: 11565955
Drug: Loxoribine (doses:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxoribine (doses: 1 mg/kg, 5 mg/kg, 10 mg/kg)
Study: 8246057
Drug: Normal glucose
Normalized name: Normal Glucose Control Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal glucose levels (<= 120 mg/dl)
Study: 8246057
Drug: Hyperglycemia (>
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (> 120 mg/dl)
Study: 8246057
Drug: Normal mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal mean glucose levels (<= 120 mg/dl) between Days 3 and 7
Study: 8246057
Drug: Elevated mean
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated mean glucose levels (> 120 mg/dl) between Days 3 and 7
Study: 2937659
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment in addition to normal IVF procedures (group A)
Study: 20479335
Drug: ISMN (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISMN (10 mg)
Study: 20479335
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sildenafil (50 mg) and ISMN (10 mg)
Study: 18493713
Drug: Levetiracetam (started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (started at 250 mg qhs, increased to 1,500 mg bid as tolerated)
Study: 18493713
Drug: Levetiracetam (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (treatment phase lasted 4 months)
Study: 18493713
Drug: Levetiracetam (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (treatment for PMDD)
Study: 15780443
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (PCV) given once or twice
Study: 10627637
Drug: Intensified stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified stem cell transplant regimen (HDCT with escalated melphalan 160 mg/m2, fractionated total body irradiation 12 Gy, and infusional etoposide 60 mg/kg)
Study: 1851649
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UH) 5000 units b.d.
Study: 1851649
Drug: Logiparin 2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Logiparin 2500 units daily
Study: 1851649
Drug: Logiparin 3500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Logiparin 3500 units daily
Study: 6815282
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg weekly for six weeks
Study: 6815282
Drug: Doxycycline (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (single dose on day 3 of illness)
Study: 27596360
Drug: Serelaxin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin (75 μg/kg/day)
Study: 24401729
Drug: Internet-linked tablet
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-linked tablet computer-based intervention (the EDGE platform)
Study: 19444413
Drug: No propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No propofol therapy